“Eculizumab First” in the Management of Posttransplant Thrombotic Microangiopathy

“Eculizumab First” in the Management of Posttransplant Thrombotic Microangiopathy

Introduction: Posttransplant thrombotic microangiopathy (PT-TMA) is an uncommon event that characterizes approximately 3% to 14% of kidney transplants (KTs), and that is associated with a higher risk of delayed graft function and graft loss. PT-TMA occurs more frequently within the first 3 months af...

Full description

Saved in:

Bibliographic Details
Main Authors:	Federica Maritati, Valeria Corradetti, Claudia Bini, Michele Provenzano, Vania Cuna, Marco Busutti, Francesco Tondolo, Fulvia Zappulo, Gisella Vischini, Francesca Iacovella, Chiara Abenavoli, Greta Borelli, Marcello Demetri, Benedetta Fabbrizio, Giorgia Radi, Matteo Ravaioli, Caterina Mele, Gaetano La Manna, Giorgia Comai
Format:	Article
Language:	English
Published:	Elsevier 2024-04-01
Series:	Kidney International Reports
Subjects:	thrombotic microangiopathy atypical hemolytic uremic syndrome kidney transplant eculizumab
Online Access:	http://www.sciencedirect.com/science/article/pii/S2468024924000147
Tags:	Add Tag No Tags, Be the first to tag this record!

Similar Items

Response to Letter to the Editor From Ville S. et al. About: “Eculizumab First” in the Management of Posttransplant Thrombotic Microangiopathy
by: Federica Maritati, et al.
Published: (2024-06-01)

Risk factors for IgA nephropathy recurrence and impact on graft survival in a cohort of kidney transplanted patients
by: Angelodaniele Napoletano, et al.
Published: (2025-12-01)

Transplant-associated Thrombotic Microangiopathy: An Enigma Treated with Eculizumab
by: S. Ravitej, et al.
Published: (2024-10-01)

Eculizumab or ravulizumab treatment effect in people with neuromyelitis optica spectrum disorder: a plain language summary of three studies
by: Alfredo Damasceno, et al.
Published: (2025-02-01)

Meningococcemia in a vaccinated child receiving eculizumab and review of the literature
by: Diana Üçkardeş, et al.
Published: (2023-02-01)

Response to Letter to the Editor From Bouwmeester RN et al.: “Eculizumab in Postransplant TMA: Unproven Benefit.”
by: Federica Maritati, et al.
Published: (2024-06-01)

Effective Management of Carfilzomib-Induced Thrombotic Microangiopathy in Multiple Myeloma Using Eculizumab
by: Jennifer Kim, et al.
Published: (2025-06-01)

Response to “A Caution Against the Use of C5B-9 Endothelial Assay to Support Eculizumab Therapy”
by: Federica Maritati, et al.
Published: (2024-05-01)

Incidence of infection associated with eculizumab: a meta-analysis of 9 randomized controlled trials
by: Aidou Jiang, et al.
Published: (2025-04-01)

Method development and validation for determination of antihemolytic activity of eculizumab (Soliris)
by: E. Yu. Prudnikova, et al.
Published: (2017-03-01)

Rapid response of eculizumab: a rescue therapy for ventilator-dependent refractory myasthenic crisis
by: Yohei Takenobu, et al.
Published: (2025-05-01)

Case Report: Eculizumab in highly active myasthenia gravis complicated by severe infections
by: Yufei Deng, et al.
Published: (2025-07-01)

Adverse drug events (ADEs) risk signal mining related to eculizumab based on the FARES database
by: Xi-Feng Wang, et al.
Published: (2025-01-01)

Corrigendum: Adverse drug events (ADEs) risk signal mining related to eculizumab based on the FARES database
by: Xi-Feng Wang, et al.
Published: (2025-02-01)

Eculizumab in Posttransplant TMA: Unproven Benefit
by: Romy N. Bouwmeester, et al.
Published: (2024-06-01)

Global aHUS Registry Analysis of Patients Switching to Ravulizumab From Eculizumab
by: Franz Schaefer, et al.
Published: (2024-09-01)

Real-World effectiveness of eculizumab in atypical hemolytic uremic syndrome: a retrospective study from Western China
by: Yun Hu, et al.
Published: (2025-06-01)

Case Report: Failure of eculizumab to block complement to prevent relapse of anti-phospholipid syndrome in kidney transplant recipient
by: Thibault Laban, et al.
Published: (2025-06-01)

Development and validation of a method for determination of Eculizumab concentration in human plasma by biolayer interferometry
by: V. M. Simonov, et al.
Published: (2018-02-01)

Successful eculizumab treatment as an adjunctive therapy to desensitization in ABO-incompatible living donor kidney transplantation and its molecular phenotypes
by: Ga Young Heo, et al.
Published: (2024-10-01)

Eculizumab is efficacious and safe in pediatric patients with various forms of hemolytic uremic syndrome: a retrospective clinical experience of a tertiary center
by: Naama Lax, et al.
Published: (2025-04-01)

A hyper-acute immune hemolytic anemia induced by contrast medium was successfully treated with eculizumab: a case report
by: Sabine Hermann, et al.
Published: (2025-02-01)

Use of complement C5-inhibitor eculizumab in patients with infection-associated hemolytic uremic syndrome – a case-series report
by: Petra Varga, et al.
Published: (2025-03-01)

Treatment of atypical hemolytic uremic syndrome with eculizumab in a patient presenting with neuropsychiatric prodrome: a case report
by: Hanze Yang, et al.
Published: (2025-04-01)

Letter to the editor about: “Eculizumab First” in the Management of Posttransplant Thrombotic Microangiopathy
by: Simon Ville, et al.
Published: (2024-06-01)

Can patient self-evaluation of functional status be used for evaluation of impairment of motor function in Guillain-Barré syndrome? Mapping clinician- and patient-reported outcomes in a phase 3 study of eculizumab in Japan
by: Antoine Regnault, et al.
Published: (2025-02-01)

Coronary Artery By-Pass Grafting in Patient With Paroxysmal Nocturnal Hemoglobinuria (Case Report)
by: A. Amendola, et al.
Published: (2021-04-01)

Comparing the original and biosimilar biotherapeutics of the monoclonal antibody eculizumab by intact mass measurement and middle-up mass spectrometry analysis
by: M. B. Degterev, et al.
Published: (2021-03-01)

Deterioration in Clinical Status Is Not Enough to Suspend Eculizumab: A Genetic Complement-Mediated Atypical Hemolytic Uremic Syndrome Case Report
by: Luca Calvaruso, et al.
Published: (2019-01-01)

Pharmacotherapy of Ischemia-Reperfusion Injury of Transplanted Kidneys in Children: Comparative Study
by: Victor A. Goryainov, et al.
Published: (2017-10-01)

Navigating Hyperhemolysis in Sickle Cell Disease: Insights from Literature
by: Sruthi Vellanki, et al.
Published: (2025-07-01)

Consensus opinion on the management of patients with neuromyelitis optica spectrum diseases: issues of terminology and therapy
by: V. S. Krasnov, et al.
Published: (2022-12-01)

PLASMIC score to aid diagnosis of aHUS: an analysis of C5 inhibitor clinical trials and the PINC AI™ healthcare database
by: Miguel G. Uriol-Rivera, et al.
Published: (2025-05-01)

Exuberant Endothelial C5b-9 Formation in Recurrent and De Novo Posttransplant Thrombotic Microangiopathy
by: Sistiana Aiello, et al.
Published: (2024-11-01)

Long-term effectiveness and safety of ravulizumab in paroxysmal nocturnal hemoglobinuria: a plain language summary
by: Celso Arrais, et al.
Published: (2025-07-01)

Quantification of polysorbate 80 in biopharmaceutical formulations implementing an optimized colorimetric approach
by: A. S. Seregin, et al.
Published: (2020-07-01)

Treatment of paroxysmal nocturnal hemoglobinuria
by: I. A. Lisukov, et al.
Published: (2014-07-01)

Evaluation of Patients with Hemolytic Uremic Syndrome
by: Uğur Saraç, et al.
Published: (2025-04-01)

Ophthalmoplegia in the Acute Phase of Hemolytic Uremic Syndrome: A Case Report
by: Müge Ayanoğlu, et al.
Published: (2021-03-01)

Optic neuritis in CD59 deficiency: an extremely rare presentation
by: Çağatay Günay, et al.
Published: (2022-08-01)